INS CD-ALZHEIMER'S TREATMENT
Illinois requires insurance coverage of FDA-approved Alzheimer's treatments without prior authorization, effective immediately with full implementation by July 2027.
Illinois requires insurance coverage of FDA-approved Alzheimer's treatments without prior authorization, effective immediately with full implementation by July 2027.
SB 126 requires Illinois insurance carriers to cover Alzheimer's disease treatments, including disease-modifying monoclonal antibody therapies, without prior authorization requirements or excessive cost-sharing barriers. The bill establishes coverage standards and removes administrative obstacles to accessing emerging Alzheimer's treatments that have received FDA approval.
Alzheimer's disease affects over 120,000 Illinoisans, and newer treatments like aducanumab and lecanemab show promise in slowing cognitive decline in early-stage patients. By mandating insurance coverage without prior authorization delays, the bill aims to improve access to these treatments while reducing out-of-pocket costs that could otherwise prevent eligible patients from receiving them.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.